Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared to Pomalidomide, Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma SUCCESSOR-1
Verified

What's the purpose of this trial?

The goal of this clinical trial is to learn more about the safety and effectiveness of investigational drug Mezigdomide given in combination with approved treatments Bortezomib and Dexamethasone. Researchers will compare this investigational combination against standard of care treatments Pomalidomide, Bortezomib and Dexamethasone to learn more about how Mezigdomide works in relapsed or refractory multiple myeloma. 

This trial is currently open and accepting patients.

What will happen during the trial?

This study is being conducted in two different parts, or stages.

STAGE 1
In Stage 1, there are four planned groups, also called arms. Three of the four arms will receive different dose levels of investigational drug Mezigdomide in combination with bortezomib and dexamethasone, and one arm will receive pomalidomide, bortezomib and dexamethasone. 

STAGE 2
In Stage 2, there are two planned arms. One arm will receive investigational drug Mezigdomide (at the selected dose determined by stage 1), and approved treatments Bortezomib and Dexamethasone, and the other arm will receive comparator arm Pomalidomide, Bortezomib and Dexamethasone. 

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease based on M protein in your blood or urine.
  • have previously received between 1-3 prior lines of therapy for your myeloma.
  • must have previously received treatment with Lenalidomide.
  • have not previously received treatment with Mezigdomide or Pomalidomide.
  • have not previously received an allogeneic stem cell transplant, and have not received an autologous stem cell transplant in the previous three months before joining the study.
  • do not have known central nervous system involvement of your myeloma.

Additional eligibility criteria apply and can be explained by the study doctor. 

Additional Trial Information

Phase 3

Enrollment: 810 patients (estimated)

View More
Need Help?

Interested in joining or learning more about this trial?

(888) 828-2206

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Sharp Memorial Hospital (Amtower Cancer Institute)

San Diego, CA

Not Yet Accepting

James R Berenson, MD, Inc.

West Hollywood, CA

Open and Accepting

Florida

Advanced Research

Coral Springs, FL

Open and Accepting

Georgia

University Cancer and Blood Center

Athens, GA

Open and Accepting

Illinois

University of Illinois at Chicago

Chicago, IL

Not Yet Accepting

Kansas

Central Care Cancer Center (Heartland)

Garden City, KS

Open and Accepting

University of Kansas Cancer Center

Kansas City, KS

Open and Accepting

Louisiana

Tulane Cancer Center Tulane University School of Medicine

New Orleans, LA

Open and Accepting

Massachusetts

Dana-Farber Cancer Institute (Main)

Boston, MA

Not Yet Accepting

Michigan

University of Michigan Comprehensive Cancer Center Rogel Cancer Center

Ann Arbor, MI

Open and Accepting

Mississippi

Hattiesburg Clinic

Hattiesburg, MS

Open and Accepting

New Jersey

Astera Cancer Care

East Brunswick, NJ

Open and Accepting

New Mexico

University of New Mexico Comprehensive Cancer Center - New Mexico Cancer Research Alliance (NMCRA)

Albuquerque, NM

Not Yet Accepting

New York

Jonah Cancer Care Center & ECMC

Buffalo, NY

Not Yet Accepting

Northwell Health Center for Advanced Medicine Monter Cancer Center

Lake Success, NY

Open and Accepting

Rochester General Hospital

Rochester, NY

Open and Accepting

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Not Yet Accepting

Ohio

Cleveland Clinic - Taussig Cancer Center Taussig Cancer Institute

Cleveland, OH

Open and Accepting

Pennsylvania

West Penn Hospital (Allegheny Health Network)

Pittsburgh, PA

Not Yet Accepting

WellSpan Health-York Cancer Center

York, PA

Open and Accepting

Tennessee

West Cancer Center (East Campus - Germantown) East Campus

Germantown, TN

Open and Accepting

Texas

MD Anderson Cancer Center The University of Texas

Houston, TX

Open and Accepting

UT Health San Antonio MD Anderson Cancer Center Mays Cancer Center

San Antonio, TX

Not Yet Accepting

Utah

Utah Cancer Specialists Cancer Center

Salt Lake City, UT

Open and Accepting

Virginia

Hematology Oncology Associates of Fredericksburg Inc

Fredericksburg, VA

Open and Accepting

Washington

VA Puget Sound Health Care System

Seattle, WA

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

Learn more about how we work with trial sponsors